Premium
Assessment of the Albuscreen microalbuminuria kit in diabetic outpatients
Author(s) -
Leedman Peter J.,
Nankervis Aiison,
Goodwin Maxwell,
Ratnaike Sujiva
Publication year - 1987
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1987.tb133456.x
Subject(s) - microalbuminuria , albuminuria , urine , medicine , diabetic nephropathy , diabetes mellitus , urology , proteinuria , radioimmunoassay , endocrinology , kidney
Diabetic patients who have albumin excretion rates of greater than 30 (jg/min (30 mg/L at normal urine volumes) are at increased risk of the development of diabetic nephropathy. The Albuscreen microalbuminuria kit detects albuminuria at concentrations of 30 mg/L and above by an agglutination‐inhibition reaction. One hundred and ninety‐five random urine samples from diabetic outpatients were assessed by Albuscreen and Albustix testing for albuminuria and the results were correlated with those of a sensitive radioimmunoassay technique. Albuscreen testing was simple, easy to use and had a sensitivity of 96%, with a specificity of 88%. Albustix testing at a detection level of 50 mg/L revealed a sensitivity of 100% and a specificity of 68% (43 samples, false‐positive “trace” readings), while, at 30 mg/L, the sensitivity and specificity were 90% and 71%, respectively. Therefore, Albuscreen testing is well suited as a screening test for the presence of microalbuminuria in a diabetic outpatient setting. However, the role of Albustix in screening for microalbuminuria is less well defined, especially at the 30 mg/L level of detection, and requires further investigation.